NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis $1.74 -0.01 (-0.57%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aadi Bioscience Stock (NASDAQ:AADI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aadi Bioscience alerts:Sign Up Key Stats Today's Range$1.72▼$1.8250-Day Range$1.68▼$2.0952-Week Range$1.21▼$3.81Volume19,249 shsAverage Volume261,100 shsMarket Capitalization$42.97 millionP/E RatioN/ADividend YieldN/APrice Target$1.67Consensus RatingHold Company Overview Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California. Read More Aadi Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreAADI MarketRank™: Aadi Bioscience scored higher than 10% of companies evaluated by MarketBeat, and ranked 887th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingAadi Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAadi Bioscience has received no research coverage in the past 90 days.Read more about Aadi Bioscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aadi Bioscience are expected to grow in the coming year, from ($2.04) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aadi Bioscience is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aadi Bioscience is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAadi Bioscience has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aadi Bioscience's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AADI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAadi Bioscience does not currently pay a dividend.Dividend GrowthAadi Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AADI. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for AADI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aadi Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aadi Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders37.30% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aadi Bioscience's insider trading history. Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address AADI Stock News HeadlinesAadi Bioscience (NASDAQ:AADI) Trading Down 3.5% - Should You Sell?July 26, 2025 | americanbankingnews.comWhitehawk Therapeutics May 2025 slides: Pivoting to ADC development with three candidatesMay 15, 2025 | uk.investing.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightMay 14, 2025 | finance.yahoo.comMarginal Benefits in High-Risk Ovarian Cancer With Addition of Bevacizumab to ChemoMay 13, 2025 | msn.comFYARRO Sets New Standard in Rare Oncology Market with Strong Growth Prospects | DelveInsightApril 17, 2025 | finance.yahoo.comWhitehawk Therapeutics files to sell 41.67M shares of common stock for holdersApril 2, 2025 | markets.businessinsider.comWhitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken PharmaceuticalsMarch 26, 2025 | finance.yahoo.comSee More Headlines AADI Stock Analysis - Frequently Asked Questions How have AADI shares performed this year? Aadi Bioscience's stock was trading at $3.15 on January 1st, 2025. Since then, AADI shares have decreased by 44.8% and is now trading at $1.74. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) issued its earnings results on Tuesday, March, 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.37. The company had revenue of $7.24 million for the quarter, compared to analysts' expectations of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%. Read the conference call transcript. When did Aadi Bioscience's stock split? Shares of Aadi Bioscience reverse split on the morning of Friday, August 27th 2021.The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aadi Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Moderna (MRNA), NVIDIA (NVDA) and Alphabet (GOOG). Company Calendar Last Earnings3/18/2025Today8/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AADI CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Aadi Bioscience$1.67 High Price Target$1.75 Low Price Target$1.50 Potential Upside/Downside-4.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.76 million Net Margins-246.06% Pretax Margin-246.06% Return on Equity-71.87% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.54 Sales & Book Value Annual Sales$25.07 million Price / Sales1.71 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.41Miscellaneous Outstanding Shares24,697,000Free Float15,485,000Market Cap$42.97 million OptionableOptionable Beta0.68 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:AADI) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.